{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T17:10:05Z","timestamp":1755882605784,"version":"3.44.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Severe cutaneous adverse reactions (SCARs) are rare drug-induced eruptions, most notably Stevens\u2013Johnson syndrome\u2013toxic epidermal necrolysis (SJS-TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Their psychological impact is increasingly recognized, with UK guidelines for SJS-TEN recommending psychological evaluation, and a continuing medical education review for DRESS recommending monitoring for anxiety, depression and post-traumatic stress disorder (PTSD) for 1\u2005year. However, monitoring for adverse psychosocial outcomes has not been standardized. This scoping review aims to characterize the existing literature on psychosocial outcomes in survivors of SCARs and highlight gaps in knowledge. Following the Joanna Briggs Institute guidelines, we searched MEDLINE, Embase and PsycInfo for primary literature using terms related to SCARs and psychosocial outcomes. After screening 865 records, 24 studies were included. Of these studies, 88% investigated SJS-TEN and 21% addressed DRESS. In total, 44\u201354% and 21\u201344% of survivors of SJS-TEN and 36\u201363% and 50% of survivors of DRESS screened positive for anxiety and depression, respectively, on the Hospital Anxiety and Depression Scale. Overall, 17\u201351% of survivors of SJS-TEN and 50% of survivors of DRESS had scores indicating PTSD using variations of the Impact of Events Scale. Quality of life, fear of medications and altered relationships with medical providers were also frequently identified. The heterogeneity in outcome measures underscores the need for a specific, standardized tool to assess for psychosocial complications in survivors of SCARs. This review highlights needs for improved psychosocial support in survivors of SJS-TEN and DRESS, as well as research into psychosocial outcomes in unexplored SCARs such as acute generalized exanthematous pustulosis and generalized bullous fixed drug eruption.<\/jats:p>","DOI":"10.1093\/ced\/llaf202","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:34:17Z","timestamp":1747060457000},"page":"1755-1765","source":"Crossref","is-referenced-by-count":0,"title":["Mental health and psychosocial outcomes in survivors of severe cutaneous adverse reactions: a scoping review"],"prefix":"10.1093","volume":"50","author":[{"given":"Suyeon","family":"Hong","sequence":"first","affiliation":[{"name":"Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Quon","sequence":"additional","affiliation":[{"name":"Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A","family":"Nelson","sequence":"additional","affiliation":[{"name":"Yale Department of Dermatology, Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2025082212472895000_llaf202-B1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J Dermatol"},{"key":"2025082212472895000_llaf202-B2","doi-asserted-by":"crossref","first-page":"e0165933","DOI":"10.1371\/journal.pone.0165933","article-title":"Incidence of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLOS ONE"},{"key":"2025082212472895000_llaf202-B3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajem.2024.04.001","article-title":"High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"81","author":"van Nispen","year":"2024","journal-title":"Am J Emerg Med"},{"key":"2025082212472895000_llaf202-B4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module","volume":"7","author":"Wolfson","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082212472895000_llaf202-B5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-023-00779-3","article-title":"Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management","volume":"24","author":"Parisi","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025082212472895000_llaf202-B6","doi-asserted-by":"crossref","first-page":"adv00057","DOI":"10.2340\/00015555-3408","article-title":"Bullous drug reactions","volume":"100","author":"Mockenhaupt","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025082212472895000_llaf202-B7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2025082212472895000_llaf202-B8","first-page":"247","article-title":"Trends in mortality rates for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017","volume":"182","author":"Bettuzzi","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B9","doi-asserted-by":"crossref","first-page":"1414136","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"2025082212472895000_llaf202-B10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-0960.2011.00845.x","article-title":"Acute generalised exanthematous pustulosis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"2025082212472895000_llaf202-B11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"2025082212472895000_llaf202-B13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jfma.2021.09.025","article-title":"Analysis of severe \u00adcutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"2025082212472895000_llaf202-B15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","article-title":"Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US","volume":"158","author":"Creadore","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025082212472895000_llaf202-B16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.073","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management","volume":"90","author":"Wei","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472895000_llaf202-B18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11588460-000000000-00000","article-title":"Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"34","author":"Butt","year":"2011","journal-title":"Drug Saf"},{"key":"2025082212472895000_llaf202-B19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaip.2023.10.022","article-title":"Drug reaction with eosinophilia and systemic symptoms: medication adherence and quality of life in survivors","volume":"12","author":"Jaggers","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082212472895000_llaf202-B20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bjd.18746","article-title":"The psychological impact of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis on patients\u2019 lives: a Critically Appraised Topic","volume":"183","author":"O\u2019Reilly","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B21","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"2025082212472895000_llaf202-B22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.13375","article-title":"Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms","volume":"172","author":"Lew","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.18387","article-title":"Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients","volume":"182","author":"Ingen-Housz-Oro","year":"2020","journal-title":"Br J Dermatol"},{"volume-title":"Prevalence of anxiety and depression in a predominantly HIV-infected population with severe cutaneous adverse drug reactions","year":"2016","author":"Zitha","key":"2025082212472895000_llaf202-B25"},{"key":"2025082212472895000_llaf202-B26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/PPA.S285256","article-title":"Quality of life of drug reaction with eosinophilia and systemic symptom (DRESS) and Stevens\u2013Johnson syndrome (SJS) and\/or toxic epidermal necrolysis (TEN) patients","volume":"15","author":"Perwitasari","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2025082212472895000_llaf202-B27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1159\/000531366","article-title":"A comprehensive assessment of long-term complications in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"184","author":"Cekic","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"2025082212472895000_llaf202-B28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/bjd\/ljae154","article-title":"A qualitative study of psychological morbidity in paediatric survivors of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"191","author":"Phillips","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/bjd\/ljae334","article-title":"The quality-of-life impact of Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on patients\u2019 lives: an interpretative descriptive qualitative study","volume":"192","author":"O\u2019Reilly","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bjps.2019.07.015","article-title":"Toxic epidermal necrolysis (TEN): acute complications and long-term sequelae management in a multidisciplinary follow-up","volume":"73","author":"Caba\u00f1as Weisz","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2025082212472895000_llaf202-B31","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bjd.17267","article-title":"Post-traumatic stress disorder in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients","volume":"180","author":"Hefez","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025082212472895000_llaf202-B33","doi-asserted-by":"crossref","first-page":"AB225","DOI":"10.1016\/j.jaad.2018.05.901","article-title":"Posttraumatic stress disorder in survivors of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"79","author":"Eckert","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472895000_llaf202-B34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jdin.2023.01.012","article-title":"Physical and mental health impact of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis and post-hospital discharge care: identifying practice gaps","volume":"11","author":"Coromilas","year":"2023","journal-title":"JAAD Int"},{"key":"2025082212472895000_llaf202-B35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1346-8138.16487","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis associated with increased risk of developing psychiatric disorders: a retrospective population-based cohort study in Taiwan","volume":"49","author":"Chiang","year":"2022","journal-title":"J Dermatol"},{"key":"2025082212472895000_llaf202-B36","doi-asserted-by":"crossref","first-page":"992696","DOI":"10.3389\/ftox.2022.992696","article-title":"Visual function and quality of life in patients with Stevens\u2013Johnson syndrome who received acute protocol-based ocular care","volume":"4","author":"Shanbhag","year":"2022","journal-title":"Front Toxicol"},{"key":"2025082212472895000_llaf202-B37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bjd.20741","article-title":"A retrospective case series of paediatric Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology\u2019s National Guidelines for children and young people","volume":"186","author":"Forsyth","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025082212472895000_llaf202-B38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/jbcr\/irab109","article-title":"Physical and psychological recovery following toxic epidermal necrolysis: a patient survey","volume":"42","author":"DeNiro","year":"2021","journal-title":"J Burn Care Res"},{"key":"2025082212472895000_llaf202-B39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"issue":"Suppl. 1","key":"2025082212472895000_llaf202-B40","first-page":"S175","article-title":"Long-term outcomes of patients treated with toxic epidermal necrolysis","volume":"37","author":"Honari","year":"2016","journal-title":"J Burn Care Res"},{"issue":"Suppl. 1","key":"2025082212472895000_llaf202-B41","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/jbcr\/iry006.196","article-title":"Perspectives of Stevens\u2013Johnson and toxic epidermal necrolysis survivors on their long-term outcomes","volume":"39","author":"Dai","year":"2018","journal-title":"J Burn Care Res"},{"key":"2025082212472895000_llaf202-B42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2024.04.036","article-title":"Understanding the patient experience of drug reaction with eosinophilia and systemic symptoms: a qualitative study","volume":"91","author":"Samarakoon","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472895000_llaf202-B43","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/BF03262001","article-title":"Internet accounts of serious adverse drug reactions: a study of experiences of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Butt","year":"2012","journal-title":"Drug Saf"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf202\/63157847\/llaf202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1755\/63157847\/llaf202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1755\/63157847\/llaf202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:47:37Z","timestamp":1755881257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/9\/1755\/8129011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,12]]},"published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf202","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,12]]}}}